Holen Sie sich die Stockscreener-App
80.30
0.34%
0.27
Vorhandelsmarkt:
80.41
0.11
+0.14%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$80.03
Offen:
$80.465
24-Stunden-Volumen:
7.85M
Relative Volume:
0.54
Marktkapitalisierung:
$200.57B
Einnahmen:
$63.62B
Nettoeinkommen (Verlust:
$16.41B
KGV:
12.37
EPS:
6.49
Netto-Cashflow:
$14.72B
1W Leistung:
-0.61%
1M Leistung:
-3.67%
6M Leistung:
-6.27%
1J Leistung:
-29.24%
1-Tages-Spanne:
$79.67
$80.94
1-Wochen-Bereich:
$78.65
$81.64
52-Wochen-Spanne:
$73.31
$120.30
Merck Co Inc Stock (MRK) Company Profile
Firmenname
Merck Co Inc
Sektor
Telefon
908-740-4000
Adresse
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Vergleichen Sie MRK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
80.30 | 199.90B | 63.62B | 16.41B | 14.72B | 6.49 |
|
LLY
Lilly Eli Co
|
639.43 | 569.45B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
172.78 | 418.62B | 90.63B | 22.66B | 16.40B | 9.35 |
|
ABBV
Abbvie Inc
|
198.64 | 350.91B | 58.33B | 3.76B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
119.31 | 229.50B | 55.19B | 13.65B | 16.81B | 6.86 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2025-02-18 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-02-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-01-08 | Herabstufung | Truist | Buy → Hold |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-12-04 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-11 | Herabstufung | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-03-11 | Herabstufung | Societe Generale | Hold → Sell |
| 2024-01-04 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-27 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Hold |
| 2023-04-13 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-03-28 | Herabstufung | Societe Generale | Buy → Hold |
| 2023-03-13 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | Eingeleitet | Jefferies | Buy |
| 2023-02-22 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-10-10 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-09-14 | Hochstufung | Berenberg | Hold → Buy |
| 2022-07-06 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | Fortgesetzt | SVB Leerink | Outperform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-12-17 | Eingeleitet | Goldman | Buy |
| 2021-12-16 | Eingeleitet | Daiwa Securities | Neutral |
| 2021-12-13 | Herabstufung | UBS | Buy → Neutral |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-12-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-11-29 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-11-01 | Hochstufung | Argus | Hold → Buy |
| 2021-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-20 | Herabstufung | Argus | Buy → Hold |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | Fortgesetzt | Bernstein | Outperform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-08-03 | Hochstufung | Goldman | Neutral → Buy |
| 2020-06-12 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-08-16 | Eingeleitet | SVB Leerink | Outperform |
| 2019-07-03 | Eingeleitet | Mizuho | Buy |
| 2019-05-28 | Eingeleitet | Goldman | Neutral |
| 2019-05-13 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | Bestätigt | Citigroup | Buy |
| 2018-10-09 | Fortgesetzt | Guggenheim | Buy |
| 2018-04-23 | Hochstufung | Goldman | Neutral → Buy |
| 2018-04-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2018-03-12 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | Bestätigt | Leerink Partners | Mkt Perform |
| 2018-02-07 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2018-01-16 | Hochstufung | SunTrust | Hold → Buy |
Alle ansehen
Merck Co Inc Aktie (MRK) Neueste Nachrichten
What's Going On With Merck Stock Tuesday?Merck & Co (NYSE:MRK), Pfizer (NYSE:PFE) - Benzinga
IO Biotech's cancer vaccine shows improvement, but narrowly misses study goal - Reuters
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering - GlobeNewswire Inc.
Merck to Begin Phase 3 Trials for Investigational Monthly HIV Prevention Pill - Insider Monkey
Merck KGaA Plans $4 Billion Bond Sale to Fund SpringWorks Therapeutics Acquisition - Bloomberg
Goldman Sachs Slashes PT on Merck & Co. (MRK) to $94 From $99, Keeps a Buy Rating - MSN
Merck & Co. (MRK) Divests Surface Solutions for €665 million - MSN
Goldman Sachs Reduced the PT on Merck & Co., Inc. (MRK), Kept a Buy Rating - MSN
Verona’s COPD Launch Success Sealed Merck Buyout Interest - insights.citeline.com
Merck & Co Inc Options Trading: September 26th Expiration - AInvest
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know - Yahoo Finance
United States Pharmaceutical Market Forecast and Company Analysis Report 2025-2033 Featuring F. Hoffmann-La Roche, Novartis, Abbvie, Johnson & Johnson, Merck, Pfizer, BMS, Sanofi, GSK, Takeda - Yahoo Finance
Merck & Co. (MRK) Slid on Weaker Market Sentiment and Concerns About Drug Pipeline - MSN
10 Best Blue-Chip Stocks to Buy for the Long Term - Morningstar
11 Cheap Pharmaceutical Stocks to Buy Now - Insider Monkey
Merck & Co., Inc. (MRK) Needs To Move On From Talking About Its Animal Division, Says Jim Cramer - MSN
Merck to Cut 6,000 Jobs as It Aims for $3 Billion in Cost Savings by 2027 - PharmExec
Oppenheimer Considers Merck & Co. (MRK) Agreement as Strong Endorsement for Veeva’s Vault CRM - MSN
N.J.-based Merck announces $3B in cost cutting measures including layoffs - NJ.com
Cautious Optimism As Merck Leans On Oncology Amid Gardasil Vaccine Concerns - Benzinga
Merck & Co., Inc. (NYSE:MRK) Q2 2025 Earnings Call Transcript - Insider Monkey
Merck Layoffs Announced: Axing Both Land and Labor In One Fell Swoop - The HR Digest
Merck & Co Inc (MRK) Q2 2025 Earnings Call Highlights: Navigating Challenges with Strategic ... - Yahoo Finance
Merck & Co.’s Winrevair Growing Into The Revenue Driver Needed Post-Keytruda LOE - insights.citeline.com
Merck Stock Is Almost A Classical Benjamin Graham Investment - Seeking Alpha
Merck Q2 Earnings Top, Sales Meet Estimates, 2025 View Narrowed - TradingView
Merck will lay off employees and shed some real estate to cut $3 billion in costs - MSN
Earnings call transcript: Merck Q2 2025 beats EPS, stock dips on revenue miss - Investing.com
Why Is Merck Stock Falling On Tuesday?Merck & Co (NYSE:MRK) - Benzinga
MRK Earnings: Merck & Co Q2 adj. profit drops on lower sales - AlphaStreet
Merck Cuts $3 Billion in Costs as Keytruda Reign Nears End - MSN
Merck posts Q2 earnings miss, unveils cost-cutting initiative - Proactive financial news
Merck Mounts $3 Billion Revamp as Keytruda Price Pressure Looms - Bloomberg.com
Merck & Co., Inc. Reports Mixed Second-Quarter 2025 Results - Tokenist
Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2025 Financial Results - BioSpace
Merck & Co. Announces New Restructuring Program - TipRanks
Merck in Charts: KEYTRUDA sales surge 9% Y/Y, GARDASIL dips 54% in Q2 (NYSE:MRK) - Seeking Alpha
Merck plans $3B annual cost cuts as Keytruda faces patent cliff (MRK:NYSE) - Seeking Alpha
Merck & Co Inc. Q2 Profit Decreases, But Beats Estimates - Nasdaq
Finanzdaten der Merck Co Inc-Aktie (MRK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.18%
0.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):